DEALS: Genzyme, Isis ink $1.9B pact


Genzyme, Isis ink $1.9B pact


DEALS

WHO

WITH

WHAT

SCOOP

Genzyme

Isis Pharmaceuticals

$1.9B deal

The deal is for Isis' promising cardiovascular drug mipomersen, its flagship product. Genzyme is paying $175 million in an upfront fee and will buy five percent of the company.

Merck

Addex Pharmaceuticals

$702M licensing deal

Merck is paying $22 million up front and up to $455 million more for regulatory, sales and development milestones for ADX63365, a schizophrenia drug candidate.

Pfizer

Scil Technology

$250M licensing deal

Pfizer gains worldwide to an experimental osteoarthritis therapy under development at Germany's Scil Technology. Scil has been developing a cartilage specific growth factor--CD-RAP--to regenerate tissue in degenerative joints.

WuXi PharmaTech

Apptec

$151M buyout

WuXi gains Apptec's biologics capabilities along with U.S. market presence.

Invitrogen

CellzDirect

$57M buyout

CellzDirect provides R&D operations hepatocyte-based cell products and other services used to test new drugs.

Pfizer

Taisho

$22M deal

Japan's Taisho has granted all commercial rights to its preclinical schizophrenia drug outside of Japan to Pfizer for $22 million up front.

Ipsen

Salk Institute

$10M

Over the next three to five years, Ipsen will pay Salk $10 million dollars to research three disease areas: cancer biology, degenerative diseases and maladies associated with metabolic syndrome.

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.